Table 4.
Parameters obtained by pharmacokinetic–pharmacodynamic analysis (inhibitory E max model) relating the plasma concentrations of the d‐nebivolol enantiomer as a function of the heart rate variation induced by isometric handgrip exercise, including all investigated patients classified as extensive metabolizers of cytochrome P450 2D6 (n = 43). Data are expressed as mean (95% confidence interval)
| Parameters | Control group (n = 22) | CKD group (n = 12) | Haemodialysis (n = 10) |
|---|---|---|---|
| E max (bpm) | 11.87 (7.78, 21.09) | 15.53 (11.19, 23.80) | 11.62 (9.16, 17.43) |
| EC 50 (pg ml –1 ) | 1411.29 (1071.22, 2166.66) | 1656.11 (966.98, 3522.85) | 1254.50 (997.67, 1900.62) |
CKD, chronic kidney disease; E max, maximum heart rate variation. *One‐way analysis of variance and Tukey's post‐test, P < 0.05 (control vs. CKD) and (control vs. haemodialysis).